Ruocheng Mei.

Let’s talk strategy, science, or both.

RuochengMei@gmail.com
© 2026 Ruocheng MeiUCL · Pharmacology × Market Strategy
Ruocheng Mei.

Pharma market strategy · Competitive intelligence · BD

London → Shenzhen

Science Signal Strategy.

UCL graduate combining pharmacology and biologics research with biotech market strategy: oncology competitive landscapes, market-entry strategy, and AI multi-agent automation.

Open to Market StrategyCompetitive IntelligenceBusiness DevelopmentMarket Strategy

From the lab bench → the market map

Scroll ↓

1st Class Honours, BSc Biomedical Science, UCL
Hours teaching A-Level Biology and BBO
A-Level students achieved A/A* grades
2nd Place, UCL School of Pharmacy Innovation Competition
Silver Medal, British Biology Olympiad

Index / Explore further

Analyse. Build. Translate.

01 — Approach

Science in. Strategy out.

I read a programme the way a pharmacologist does, then frame it the way a strategist needs it, and automate the tracking so it keeps running.

Science

Pharmacology, biologics and formulation research at UCL, from SAXS at Diamond to antibody–nanoparticle conjugation.

Intelligence

Competitive landscapes in oncology: mechanism, pivotal trial design, dosing and licensing deal terms.

Strategy

Scenario analysis, me-better positioning and phased go-to-market plans with clear milestones.

Automation

Claude-based multi-agent workflows that keep regulatory, pipeline and deal intelligence flowing.

02 — Experience

What I’ve been building

03 — Intelligence engine

My competitor-tracking system

A Claude-based multi-agent workflow I built at Ionova Bio. Every 4 days it scans four sources and turns them into one structured briefing. Click any part, or run a cycle.

Sources

04 — Education

University College London

MSc · MeritSep 2024 – Sep 2025

Pharmaceutical Formulation and Entrepreneurship

Dissertation: Optimisation of maleimide and carbodiimide chemistry for antibody (bevacizumab)–PLGA nanoparticle coupling.

  • Analysis & Quality Control
  • Regulatory Affairs & Quality Assurance
  • Formulation of Cosmeceuticals
  • Entrepreneurial Finance
BSc · First Class HonoursSep 2021 – Jun 2024

Biomedical Science: Drug Mechanism

A grounding in how drugs work, from target to tissue. Final-year research on anti-COVID nanobody structure using X-ray scattering data from Diamond Light Source.

  • Mechanisms of Drug Action
  • Pharmacology of Inflammation
  • Drug Design & Development
  • Immunology
  • Essential Molecular Biology
  • Membrane Trafficking & Mechanisms of Disease

05 — Research

Hands-on science

MSc dissertation · Jan 2025 – Sep 2025

Bevacizumab–PLGA Nanoparticle Conjugates

Up to 43%more antibody attached at an optimised 1:1 molar ratio

Compared maleimide and carbodiimide (EDC/NHS) conjugation for an antibody–PLGA active-targeting system. Fabricated 2% PLGA nanoparticles by electrospray (450 ± 63 nm by SEM), showed maleimide chemistry gave superior antibody binding by ELISA and DLS, and validated low-temperature storage over 2 months as best for charge stability and antibody activity.

  • Electrospray
  • SEM
  • ELISA
  • DLS
  • Maleimide
  • EDC/NHS
MSc project · Aug 2024 – Jan 2025

3D-Printed Sorafenib Tablets

200–400 mgprecise, clinically relevant doses

Developed oral tablets of the poorly soluble anti-cancer drug sorafenib tosylate by semi-solid extrusion (SSE) 3D printing, for flexible dosing and controlled release. Optimised a PVPK30/HPMC/PEG400 matrix (10:8:8), confirmed 70% amorphisation, and measured release kinetics by HPLC-based in vitro dissolution testing.

  • SSE 3D printing
  • Rheometry
  • FTIR
  • P-XRD
  • DSC
  • HPLC
Undergraduate research · Nov 2023 – Aug 2024

Anti-SARS-CoV-2 Nanobody C5 Trimer Structure

5concentrations analysed for receptor/nanobody binding ratio

Collected X-ray scattering (SAXS) data at the Diamond Light Source synchrotron and combined it with AlphaFold modelling. Purified the C5 trimer on an ÄKTA system, used analytical ultracentrifugation sedimentation velocity to determine molecular weight and binding ratios, and confirmed molecular mass by mass spectrometry.

  • SAXS
  • AlphaFold
  • ÄKTA
  • AUC
  • Mass spectrometry
Course project · Jan 2024 – Jun 2024

Physicochemical Characterisation of Formulations

Characterised MAN/PVP films and freeze-dried powders at different ratios, analysing crystallinity, thermal stability and hydrogen bonding.

  • SEM
  • TGA/DSC
  • XRD
  • FTIR

06 — Skills

The toolkit

Industry analysis

Pipeline benchmarking, clinical trial design review, market-entry strategy; ClinicalTrials.gov, PubMed

Tools

Claude Code, Codex (multi-agent workflows); Origin, Stata; Adobe Creative Suite; Microsoft Office (PowerPoint)

Laboratory

SAXS, AUC, ÄKTA purification, mass spectrometry, electrospray, SSE 3D printing, ELISA, DLS, HPLC, rheometry, SEM, TGA/DSC, XRD/P-XRD, FTIR

Languages & certifications

English (IELTS 7.5), Mandarin (native); ICH Good Clinical Practice (Coursera); British Biology Olympiad Silver Medal; CPR & First Aid

07 — Contact

Let’s talk strategy, science, or both.

Open to pharma market strategy, competitive intelligence and business development roles.

Email me → Back to top ↑